Btg Share Discussion Threads

[bargainbob] 05/4/2016 07:33

To be fair rather boring statement. Steady the ship reduce costs no further investment then put it up for sale.

Looks like currency headwinds saved the day lol.

[steeplejack] 05/4/2016 07:26

Yes,the jury remains out on Varithena but the overall guidance is for revenue growth at the higher end which should steady the ship.

[king1pin2] 05/4/2016 07:20

I would have thought that the news was good on Varithena with progress being made and improving insurance coverage in acceptable timeframes, This was in the price as they say so i would expect an uplift in the shares today.

[king1pin2] 05/4/2016 07:12

steady as she goes as the man above says, bang on and happy with the guidance.

[bill hunt] 05/4/2016 07:09

Steady as she goes. No real waves or surprises

[bargainbob] 04/4/2016 12:32

range could be £5 or £7 tomorrow

[fhmktg] 04/4/2016 08:23

Don't hold your breath,BB and Greg.I don't anticipate anything other than 'Steady as she goes' message on the codes for Varithena,but that is already in the share price The news on beads and the rest of the intervention sectors should be better and even Crofab could get a boost from dealing with less serious bites. The dollar/ sterling effect could put a few pounds in the kitty.IMHO it is 2016/17 that will see the top line grow faster and divi could be 2018 or later. I'll be up with a cup of tea at 7am tomorrow. Keep the faith!

[bargainbob] 03/4/2016 15:06

Would like to see a share divi given at the very least.

[gregsc] 03/4/2016 14:52

Let's hope they are, or significant progress.

[bargainbob] 03/4/2016 12:56

Should be a very good week if the codes are sorted.

[bill hunt] 03/4/2016 12:31

5th April pre close update.

[bill hunt] 03/4/2016 12:31

sorry double post.

[fhmktg] 01/4/2016 16:33

That's better.

[fhmktg] 01/4/2016 13:24

Another advance in difficult treatments and the market reaction....zip!Let's see what the US makes of it and the analysts over the weekend, but I despair sometimes the real insight the market has for genuine innovation by British companies!

[bookish] 01/4/2016 12:12

BTG Announces US Launch of LC Bead LUMI, Ground-Breaking Radiopaque Embolic Bead
BTG.L - PR Newswire

01-APR-2016 12:00:12

First and only, commercially available, radiopaque embolic bead in the US has potential to revolutionize treatment of hypervascular tumors and arteriovenous malformations

LONDON, April 1, 2016 /PRNewswire/ --

BTG plc (LSE: BTG), a global specialist healthcare company, today announced the launch of LC Bead LUMI in the US, the first commercially available radiopaque embolic bead for the embolization of hypervascular tumors and arteriovenous malformations (AVMs). LC Bead LUMI is a next generation development of LC Bead®, the market leading embolic bead.


The unique visibility of LC Bead LUMI during and after embolization supports the optimization of patient treatment by enabling real-time visible confirmation of bead location during the procedure. This provides interventional radiologists more control, while at the same time facilitating discovery of regions of under-treatment, allowing precise evaluation of the completeness of tumor treatment and enhanced end-point determination, with long-lasting radiopacity to support follow-up management.

"The launch of LC Bead LUMI has the potential to be a real game-changer in the field of embolization," commented Raj Narayanan, Associate Professor of Clinical Radiology at the University of Miami. "Not only does it provide doctors and patients with reassurance that the tumor has been treated in its entirety, but it allows interventional radiologists like me to refine treatment as we go, with the subsequent prospect of improved outcomes for patients."

LC Bead LUMI has been developed on the same technology platform and to the same high standard as LC Bead®, building upon its market leading clinical performance.

"With the launch of LC Bead LUMI, BTG is helping to ensure embolization technology achieves its full potential," commented Ken Pugh, BTG Vice President, Commercial Development and Interventional Oncology Marketing, the Americas. "The potential benefits of LC Bead LUMI are significant - it represents a new level of control and offers the unique opportunity to individualize patient treatment in order to help doctors see more and treat smarter, while at the same time providing reassurance to patients that the treatment is getting to where it needs to be. At BTG, we're passionate about the potential of LC Bead LUMI and the power of interventional oncology to improve human health."

Today's launch represents the first market commercialization for LC Bead LUMI, with regulatory clearances and launches planned for additional radiopaque bead products worldwide.

[a1ord53] 01/4/2016 11:00

01 Apr 16 RBC Capital Markets Outperform 620.25 820.00 820.00 Reiterates

[gregsc] 30/3/2016 10:17

Close period update 5th April

[semper vigilans] 21/3/2016 10:03

Angle have developed a testing system with Barts that will be more specfic and encourage its wider, but more targeted usage?

[fhmktg] 21/3/2016 09:50

Is this rise just trading or due to the extension of Arbiraterone useage in the UK?

[bargainbob] 16/3/2016 12:15

hxxp://www.cityam.com/236879/pharmaceutical-companies-vectura-and-skyepharma-announce-4413m-merger

[semper vigilans] 16/3/2016 11:35

Vectura and Skypharma episode leaves BTG slightly more vulnerable?

[fhmktg] 09/3/2016 20:01

Great news- new lease of life for CroFab?

[bookish] 09/3/2016 18:04

New Data from Largest Prospective Study on CroFab for Treatment of Copperhead Snake Envenomation BTG.L - PRN

09-MAR-2016 17:00:03


Results Demonstrate Reduced Disability for Patients Treated with CroFab®

LONDON, March 9, 2016 /PRNewswire/ -- BTG plc (LSE: BTG) announced today the
presentation of new data from the largest prospective study ever conducted in
the treatment of copperhead snake envenomation. This study builds on the
extensive body of evidence supporting the safety and efficacy of CroFab
Crotalidae Polyvalent Immune Fab (Ovine) in treating copperhead snake
envenomation. The data were shared in a keynote presentation at the Venom Week V
International Scientific Symposium (March 9-12) in Greenville, NC.
A randomized, double-blind, placebo-controlled study compared CroFab versus placebo for the treatment of copperhead snake envenomation in 74 patients (45, CroFab; 29, placebo).1 The primary study outcome was met, which was a comparison of scores on the Patient Specific Functional Scale (PSFS) - a measure of a patient's ability to do activities he or she enjoys 14 days after treatment. Patients treated early with CroFab were more fully recovered (day 14 least squares mean PSFS score difference +1.176, p=0.036). Other study measures, including limb-specific outcome tools, grip strength, physical function-related quality of life, and pain medication use, broadly supported the primary study outcome.

Principal investigator, Eric Lavonas, MD, FACEP, FACMT, of the Rocky Mountain Poison and Drug Center - Denver Health and the University of Colorado, commented: "Although highly purified antivenom has been available for 16 years, this is the first clinical trial to look at whether giving antivenom to patients whose snakebites were not life-threatening helps them recover more quickly. The results are clear. The patients who received antivenom got back to doing the activities they enjoy more quickly."

The study also sought to determine if early administration of CroFab reduced the likelihood or severity of long-term limb dysfunction in patients following envenomation.2 The results demonstrated that patients treated with CroFab following copperhead envenomation tended to have better function in their limbs and increased ability to do activities they enjoy than patients treated with placebo.3

The most common adverse events experienced by >5% of patients overall or within treatment group included headache (11.1% in the CroFab group vs 6.9% in the placebo group), pruritus (11.1% vs 3.4%), urticaria (11.1% vs 0%), nausea (8.9% vs 6.9%), dizziness (8.9% vs 3.4%), pyrexia (8.9% vs 0%), paraesthesia (6.7% vs 0%), rash (6.7% vs 0%), and pain in extremity (6.7% vs 0%).1

CroFab is the only U.S. Food and Drug Administration (FDA) approved treatment indicated for the management of patients with North American crotalid envenomation.1 Crotalids, also known as pit viper snakes, include rattlesnakes, copperheads, and cottonmouths/water moccasins.